The development of targeted therapeutics crucially relies on the identification of target antigens, which are specifically expressed at the site of disease and which are readily accessible for agents coming from the bloodstream.
In collaboration with ETH Zurich, Philochem has pioneered chemical proteomics methods for the characterization of accessible markers of pathology, which can be drugged by antibodies and small molecule ligands. In a simple set-up, cell lines can be submitted to surface biotinylation followed by capture on streptavidin resin and mass spectrometric analysis of tryptic peptides. In a more complex set up, in vivo biotinylation procedures of rodent models of pathology enable the chemical proteomic characterization of vascular proteins in health and in disease. The technology has been extended to the ex vivo perfusion of surgically-resected human organs with cancer.
Elia et al. (2014) J Proteomics, 107, 50-5
Neri and Supuran (2011) Nat Rev Drug Discov, 10, 767-77
Fugmann et al. (2011) Kidney Int, 80, 272-81
Roesli et al. (2011) J Proteomics, 74, 539-46
Schliemann et al. (2010) Blood, 115, 736-44
Borgia et al. (2010) Cancer Res, 70, 309-18
Fugmann et al. (2010) Proteomics, 10, 2631-43
Rösli et al. (2008) Methods Mol Biol, 418, 89-100
Conrotto et al. (2008) Int J Cancer, 123, 2856-64
Castronovo et al. (2006) Mol Cell Proteomics, 5, 2083-91
Brack et al. (2006) Clin Cancer Res, 12, 3200-8
Scheurer et al. (2005) Proteomics, 5,2718-28
Rybak et al. (2005) Nat Methods, 2, 291-98
Neri and Bicknell (2005) Nat Rev Cancer, 5,436-46